GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Pretax Margin % is 25.18% as of Mar. 2026, which is 74% above its 10-year median of 14.50. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 89.09% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
GlaxoSmithKline Pakistan Pretax Margin % Related Terms
GlaxoSmithKline Pakistan Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Pretax Margin % of 25.18% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 74% above median its historical median of 14.50. Over the past decade, GlaxoSmithKline Pakistan's Pretax Margin % has ranged from 4.25 to 25.98. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #104 out of 953 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is GlaxoSmithKline Pakistan's Pretax Margin % too high?
GlaxoSmithKline Pakistan's current Pretax Margin % of 25.18% is 74% above median its 10-year median of 14.50. Over the past 10 years, this metric has ranged from a low of 4.25 to a high of 25.98. The Drug Manufacturers industry median Pretax Margin % is 7.30. GlaxoSmithKline Pakistan's value of 25.18% is 244.9% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #104 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #104 out of 953 companies for Pretax Margin %. This places GlaxoSmithKline Pakistan in the top 11% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. GlaxoSmithKline Pakistan's value of 25.18% is 244.9% above this benchmark. Historically, GlaxoSmithKline Pakistan's own Pretax Margin % has ranged from 4.25 to 25.98 over the past decade. While the company's 10-year median is 14.50 vs. the industry median of 7.30, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Pretax Margin % of 25.18% is 244.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Pretax Margin % is 25.18%, which is 74% above median its own 10-year median of 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Pretax Margin % is 25.18%, which is 74% above median its 10-year median of 14.50 and 244.9% above the Drug Manufacturers industry median of 7.30. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Pretax Margin % is 25.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Pretax Margin %: 25.18% (74% above median its 10-year median of 14.50)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 244.9% above the Drug Manufacturers median (#104 of 953)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
